Cre-Aid Labs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.11 M
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -82.19%
- Profit Growth -110.30%
- Ebitda -96.23%
- Net Worth -5.63%
- Total Assets -45.44%
About Cre-Aid Labs
Cre-Aid Labs Private Limited (CLPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 05 October 2020 (Four years and four months 17 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Amartya Gupta and Satyam Chaturvedi serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U33309KA2020PTC139331
- Company No.
139331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Oct 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Cre-Aid Labs Private Limited offer?
Cre-Aid Labs Private Limited offers a wide range of products and services, including Physiotherapy & Rehab Aids, Rehab Splints.
Who are the key members and board of directors at Cre-Aid Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyam Chaturvedi  | Director | 05-Oct-2020 | Current |
| Amartya Gupta | Director | 05-Oct-2020 | Current |
Financial Performance of Cre-Aid Labs.
Cre-Aid Labs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 82.19% decrease. The company also saw a substantial fall in profitability, with a 110.3% decrease in profit. The company's net worth dipped by a decrease of 5.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cre-Aid Labs?
In 2022, Cre-Aid Labs had a public holding of 2.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cre-Aid Labs?
Unlock and access historical data on people associated with Cre-Aid Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cre-Aid Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cre-Aid Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.